Fractyl Health, Inc. Common Stock (GUTS) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.59 (+0.59%), Market cap $0.14B, 52-week low–high $0.39 ~ $2.88.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and chan
Financial statements, price targets, institutional (13F) holdings and related news for Fractyl Health, Inc. Common Stock are updated in real time on BlackAll Trade.
Fractyl Health, Inc. Common Stock trades at $0.59 (+0.59%). Real-time quotes and charts are available on BlackAll Trade.
Fractyl Health, Inc. Common Stock has a market cap of about $0.14B.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural ther